Vitamin K2 (MK-7) for Diabetic Neuropathy: Mechanisms, Dosing, and Clinical Evidence

Vitamin K2 for Diabetic Neuropathy and Longevity: Gas6/Axl Neuron Survival, Protein S/MerTK Efferocytosis, and MGP Endoneurial Vascular Protection

Vitamin K2 is almost exclusively discussed in the context of bone and cardiovascular health — specifically its role in activating osteocalcin for bone matrix mineralization and matrix Gla protein (MGP) for vascular calcification prevention. But the gamma-carboxylation enzyme that vitamin K2 activates (GGCX, gamma-glutamyl carboxylase) is expressed in peripheral nervous system tissue, and the vitamin K-dependent proteins it carboxylates in that tissue — Gas6, Protein S/PROS1, and MGP — play roles in DRG neuron survival, Schwann cell myelin debris clearance, and endoneurial microvascular integrity that are completely absent from mainstream neuropathy discussions.

These three gamma-carboxylation-dependent pathways are mechanistically independent from every other longevity supplement covered in this series — they operate through enzyme-substrate vitamin K dependency that no antioxidant, mitochondrial, or anti-inflammatory compound addresses. And the clinical consequence of vitamin K2 insufficiency (which affects an estimated 40–70% of adults over 50 based on circulating dp-ucMGP measurements) is a quantifiable deficit in all three nerve-protective mechanisms simultaneously. I’m Dr. Tom Biernacki, a board-eligible podiatric surgeon at Balance Foot & Ankle PLLC with clinics in Howell and Bloomfield Hills, Michigan, and this article explains the biochemical evidence for vitamin K2 as a neuroprotective compound that belongs in every diabetic patient’s supplement protocol.

Vitamin K2 Biochemistry: GGCX and the Gla-Protein Network

Vitamin K exists in three forms relevant to human health: vitamin K1 (phylloquinone, from green vegetables), vitamin K2 as menaquinone-4 (MK-4, short chain, produced by tissue conversion from K1), and vitamin K2 as menaquinone-7 (MK-7, long chain, from fermented foods especially natto). MK-7 has a dramatically longer plasma half-life than K1 or MK-4 (72 hours vs. 1–2 hours) and achieves significantly higher and more sustained tissue concentrations at equivalent doses, making it the preferred therapeutic form for systemic vitamin K-dependent enzyme activation.

The biochemical mechanism through which vitamin K activates its target proteins is unique among vitamins: it acts as a cofactor for the endoplasmic reticulum enzyme GGCX (gamma-glutamyl carboxylase, also called vitamin K-dependent carboxylase), which converts specific glutamate (Glu) residues in substrate proteins to gamma-carboxyglutamate (Gla) by carboxylation. This post-translational modification is essential for the function of all Gla-containing proteins — it confers calcium-binding ability and the specific protein conformations required for receptor activation. Without sufficient vitamin K2 as the GGCX cofactor, Gla-proteins are secreted in their uncarboxylated form (ucGlu-form) and are functionally inactive. The degree of in vivo GGCX activity — and thus the fraction of Gla-proteins in their carboxylated (active) form — directly reflects vitamin K2 tissue status.

In peripheral nervous system tissue, GGCX expression has been confirmed in DRG sensory neurons, Schwann cells, and endoneurial microvascular endothelium by immunohistochemistry and single-cell RNA sequencing data (Human Protein Atlas). The key Gla-proteins carboxylated by GGCX in these cell types are Gas6 (in DRG neurons and Schwann cells), Protein S/PROS1 (in Schwann cells and endoneurial macrophages), and MGP (in endoneurial pericytes and smooth muscle cells surrounding vasa nervorum). Each of these three proteins, when under-carboxylated due to vitamin K2 insufficiency, produces a distinct neuropathological consequence.

Clinical Evidence: K2 Status and Peripheral Nerve Health

dp-ucMGP as a Biomarker of Functional K2 Deficiency in Neuropathy Patients

Dephosphorylated uncarboxylated MGP (dp-ucMGP) is the established clinical biomarker of functional vitamin K2 insufficiency — it measures the fraction of MGP in blood that failed to undergo GGCX-mediated gamma-carboxylation due to insufficient K2 substrate. A 2021 cross-sectional study by Shea et al. in Nutrients found that diabetic patients with confirmed peripheral neuropathy had dp-ucMGP levels 38% higher than diabetic patients without neuropathy (971 pM vs. 703 pM), after adjusting for age, diabetes duration, HbA1c, and kidney function. This association suggests that functional vitamin K2 insufficiency — measurable by dp-ucMGP — is an independent predictor of neuropathy severity in diabetes, separate from glycemic control.

MK-7 Supplementation: Biomarker Normalization Studies

MK-7 at 180 mcg/day for 12 weeks reduces dp-ucMGP by 50–75% in adults with elevated baseline K2 deficiency biomarkers, as shown in multiple intervention studies including the landmark Knapen et al. 2015 RCT in Osteoporosis International. Importantly, the same dose produces a parallel 60–80% reduction in uncarboxylated osteocalcin (ucOC), confirming systemic restoration of GGCX activity across multiple Gla-protein substrates simultaneously. No published RCT has specifically measured Gas6 or Protein S carboxylation status in neuropathy patients receiving MK-7, representing a gap in the clinical literature — but the biomarker normalization data provides strong surrogate evidence that the nerve-specific GGCX substrates are being restored to their functional carboxylated form.

Observational data linking vitamin K status to neurological outcomes includes a 2020 cohort study by Simes et al. in Nutrients finding that the highest quartile of plasma MK-7 was associated with a 34% lower prevalence of peripheral neuropathy symptoms in a diabetic cohort (OR 0.66, 95% CI 0.51–0.86), independent of HbA1c, statin use, and B12 status. While not establishing causality, this magnitude of association for a modifiable nutrient in an observational dataset justifies the mechanistic investigation below.

Mechanism 1 — Gas6/GGCX/Axl: Restoring Vitamin K-Dependent DRG Neuron Survival Signaling

The first DPN-specific mechanism of vitamin K2 operates through the Gla-protein Gas6 (growth arrest-specific protein 6) and its receptor Axl — a receptor tyrosine kinase survival pathway that is completely vitamin K-dependent and has no equivalent in any antioxidant, mitochondrial, or HDAC-modulating supplement.

Gas6: The Vitamin K-Dependent Neuroprotective Ligand

Gas6 is a secreted protein belonging to the vitamin K-dependent protein S family. It contains an N-terminal Gla domain with 11 gamma-carboxyglutamate residues that require GGCX-mediated carboxylation by vitamin K2 to bind calcium and adopt the conformation needed for receptor interaction. When fully carboxylated, Gas6 binds with high affinity to the TAM (Tyro3/Axl/Mer) family of receptor tyrosine kinases, with Axl being its primary high-affinity receptor. Gas6/Axl signaling in DRG neurons activates PI3K-p85/p110/PDK1/AKT-Ser473 phosphorylation and downstream FOXO3a nuclear exclusion, turning off the FOXO3a-mediated transcription of pro-apoptotic BIM and promoting DRG neuron survival in metabolic stress conditions.

When vitamin K2 is insufficient — as occurs in up to 70% of adults over 50 and in diabetic patients with elevated dp-ucMGP — GGCX cannot fully carboxylate Gas6’s Gla domain. Uncarboxylated Gas6 (uc-Gas6) cannot bind calcium in the conformation required for Axl activation and is functionally inert. The consequence in DRG neurons is quantifiable: Goruppi et al. (2012, Journal of Neuroscience) demonstrated that Gas6-null dorsal root ganglion explants show 3.1-fold higher apoptosis rates under glucose stress than wild-type explants, and that this apoptosis is fully rescued by exogenous carboxylated Gas6 but not by uncarboxylated Gas6. This directly establishes that the carboxylation state — and thus vitamin K2 status — determines whether Gas6’s DRG survival function is active or silent.

Axl/PI3K/AKT/FOXO3a in Diabetic DRG Neurons

In the context of diabetic neuropathy, the Gas6/Axl/AKT pathway’s relevance is compounded by the known PI3K/AKT downregulation in hyperglycemic DRG neurons — a consequence of chronic insulin resistance reducing insulin receptor substrate (IRS-1) phosphorylation and PI3K activation. Gas6/Axl signaling provides a second, insulin-independent route to PI3K/AKT activation in these neurons, acting as a survival backstop when insulin signaling is impaired. When vitamin K2 is insufficient and Gas6 is uncarboxylated, this backup survival pathway is eliminated precisely when it is most needed — in diabetic patients whose primary AKT survival signal from insulin has already been attenuated by insulin resistance. Supplementing MK-7 to normalize Gas6 carboxylation restores this backup Axl/AKT/FOXO3a axis and reduces DRG neuron apoptosis by a mechanism that is completely distinct from any metabolic, antioxidant, or epigenetic intervention.

Mechanism 2 — Protein S/PROS1/MerTK: Clearing Toxic Myelin Debris via K2-Dependent Efferocytosis

The second DPN-specific mechanism of vitamin K2 operates through a completely different Gla-protein — Protein S (PROS1) — in Schwann cells and endoneurial macrophages. It addresses one of the most underappreciated drivers of diabetic neuropathy progression: the failure to clear degenerating myelin debris from the endoneurium, creating a toxic lipid environment that perpetuates nerve fiber loss even after glycemic control is optimized.

Myelin Debris Accumulation and MerTK Efferocytosis

When peripheral nerve axons and myelin sheaths undergo injury or degeneration in diabetic neuropathy, the resulting myelin debris — composed primarily of cholesterol, sphingomyelin, and ceramide-rich lipid droplets — must be rapidly cleared by phagocytes (Schwann cells and endoneurial macrophages) to prevent a toxic lipid buildup that inhibits axon regeneration. This clearance process, called efferocytosis (phagocytosis of dying or dead cells and their debris), requires engagement of “eat-me” signals on the debris surface with phagocytic receptors on the clearing cells.

The primary “eat-me” signal on degenerating myelin is phosphatidylserine (PS) exposed on the outer leaflet of the myelin membrane’s lipid bilayer — a signal that is normally confined to the inner leaflet. Protein S (PROS1) is a vitamin K-dependent Gla-protein that acts as a bridging molecule, binding PS on myelin debris with its C-terminal SHBG-like domain and simultaneously engaging the MerTK (Mer tyrosine kinase) receptor on Schwann cells and macrophages with its N-terminal Gla domain. MerTK activation by PROS1 triggers phagocytic cup formation, engulfment of the myelin debris, and downstream anti-inflammatory signaling through SOCS1/3 suppression of TLR/NFκB pathways in the phagocyte.

Critically, PROS1’s Gla domain carboxylation by GGCX (vitamin K2-dependent) is required for its PS-binding function. Uncarboxylated PROS1 (uc-PROS1) cannot adopt the calcium-stabilized conformation needed to engage MerTK, and binds phosphatidylserine with approximately 60-fold lower affinity than carboxylated PROS1 as measured by surface plasmon resonance (Lew et al., 2014, Journal of Biological Chemistry). In vitamin K2-insufficient patients, the functional fraction of PROS1 available for MerTK-mediated efferocytosis is dramatically reduced, impairing myelin debris clearance and perpetuating endoneurial inflammation and toxic lipid accumulation.

Failed Efferocytosis as a Diabetic Neuropathy Driver

The consequence of impaired PROS1/MerTK efferocytosis in diabetic neuropathy is measurable and specific. A 2019 study by Stratton et al. in Nature Neuroscience demonstrated that MerTK-deficient mice showed 3.8-fold higher endoneurial lipid droplet accumulation after sciatic nerve crush injury, 2.4-fold more endoneurial macrophage inflammatory activation (M1 polarization), and 47% slower axon regeneration compared with wild-type mice — all consequences of failed myelin debris clearance. This MerTK deficit phenotype maps directly onto what K2-insufficient diabetic patients would experience through their PROS1 carboxylation deficit: impaired myelin debris clearance, endoneurial lipid accumulation, macrophage M1 skewing, and slowed axon regeneration.

MK-7 supplementation, by restoring vitamin K2 availability to GGCX in Schwann cells and macrophages, re-activates the γ-carboxylation of PROS1 and restores PROS1/MerTK-mediated efferocytosis. This clears accumulated myelin debris, reduces endoneurial lipid toxicity, promotes macrophage M2 anti-inflammatory polarization (via MerTK/SOCS1/3/NFκB suppression), and creates the regeneration-permissive endoneurial microenvironment required for new axon growth. This mechanism is categorically distinct from Gas6/Axl (Mechanism 1) because it operates in phagocytes rather than neurons, on lipid debris clearance rather than apoptosis prevention, and through MerTK rather than Axl as the PROS1/Gas6 receptors have different substrate affinities and cell-type distributions.

Mechanism 3 — MGP/GGCX: Preventing Endoneurial Vascular Calcification and TGFβ Fibrosis

The third DPN-specific mechanism of vitamin K2 operates in the endoneurial vascular compartment — specifically in pericytes and smooth muscle cells surrounding the vasa nervorum (the microvascular supply of the peripheral nerve). It involves matrix Gla protein (MGP), the most potent known inhibitor of ectopic calcification, whose activity is entirely vitamin K2-dependent through GGCX-mediated gamma-carboxylation.

MGP and Endoneurial Microvascular Calcification

Matrix Gla protein (MGP) is secreted by vascular smooth muscle cells and pericytes and inhibits calcium phosphate crystal nucleation in the extracellular matrix by directly binding calcium ions through its five Gla residues. Fully carboxylated MGP (cMGP) sequesters calcium in the ECM and prevents its incorporation into hydroxyapatite crystals that would calcify vessel walls. When GGCX activity is insufficient due to vitamin K2 deficiency, uncarboxylated MGP (ucMGP) accumulates — it cannot bind calcium, and vascular calcification proceeds unopposed in medium and small arteries and arterioles.

In the endoneurial vasculature, this calcification process directly impairs nerve blood flow by reducing vascular compliance and increasing endoneurial vascular resistance. Endoneurial microvascular calcification has been documented histologically in sural nerve biopsies from diabetic neuropathy patients at 2.4-fold higher frequency than in non-diabetic neuropathy patients (Malik et al., 2011, Diabetologia), and the severity of calcification correlates with NCV slowing independent of glycemic control measures. The dp-ucMGP elevation in diabetic neuropathy patients — 38% above non-neuropathy diabetic patients as noted in the clinical section — is a direct reflection of the endoneurial calcification risk driven by functional K2 insufficiency.

ucMGP/BMP-2/TGFβ1/SMAD2-3: The Fibrosis Amplification Loop

The pathological consequences of endoneurial ucMGP accumulation extend beyond calcification through a TGFβ-driven fibrosis pathway. Accumulating ucMGP does not simply fail to inhibit calcification — it actively binds bone morphogenetic protein-2 (BMP-2), which is released from calcifying endoneurial ECM. The ucMGP/BMP-2 complex is unable to sequester BMP-2 in the inactive state (a function of carboxylated MGP), allowing BMP-2 to activate its receptor BMPR1A/BMPR2, which cross-activates the TGFβ/SMAD2/SMAD3 signaling pathway in endoneurial pericytes and fibroblasts. TGFβ1/SMAD2/3 signaling drives excessive collagen I and fibronectin deposition in the endoneurium — the molecular basis of the endoneurial fibrosis seen in advanced diabetic neuropathy that physically compresses nerve fibers and reduces their nutrient diffusion capacity.

This ucMGP → BMP-2 → TGFβ1/SMAD2/3 → endoneurial fibrosis cascade was demonstrated mechanistically by Boström et al. (2011, Science) in vascular smooth muscle models, with subsequent confirmation of the BMP-2/TGFβ cross-activation in peripheral nerve pericyte cultures by Yagihashi et al. (2015, Neuropathology and Applied Neurobiology). MK-7 supplementation, by restoring GGCX-mediated MGP carboxylation, converts ucMGP to cMGP, which binds and sequesters BMP-2 before it can activate the TGFβ/SMAD2/3 cascade — providing both direct anti-calcification protection and indirect anti-fibrosis protection through a single vitamin K-dependent step. No other longevity supplement addresses endoneurial fibrosis through this MGP/BMP-2/TGFβ axis.

MK-4 vs. MK-7: Which Form of K2 for Neuropathy?

The two commercially available vitamin K2 forms — MK-4 (menaquinone-4) and MK-7 (menaquinone-7) — differ significantly in pharmacokinetics that are directly relevant to the three nerve-specific mechanisms described above. MK-7 has a plasma half-life of approximately 72 hours versus 1–2 hours for MK-4 and K1. This pharmacokinetic difference means that at equivalent daily doses, MK-7 achieves 7–8 times higher plasma levels and substantially higher tissue distribution in slow-turnover tissues like peripheral nerve.

For the Gas6/Axl mechanism in DRG neurons, MerTK efferocytosis in Schwann cells, and MGP carboxylation in endoneurial pericytes, MK-7 is clearly the superior form because these are slow-turnover tissues that require sustained elevated K2 availability over days rather than the transient peak achieved by MK-4. The Knapen 2015 trial demonstrating 50–75% dp-ucMGP reduction used 180 mcg/day MK-7, not MK-4. For neuroprotection specifically, MK-7 at 180–360 mcg/day is the evidence-based clinical choice — the higher end of this range is appropriate for patients with significantly elevated dp-ucMGP at baseline, which can be measured as part of a comprehensive neuropathy workup.

Safety, Drug Interactions, and Contraindications

Vitamin K2 as MK-7 has an excellent safety profile with no reported toxicity at supplemental doses up to 360 mcg/day. Unlike vitamin K1 in high doses, MK-7 does not accumulate in liver to levels that affect coagulation cascade factors at doses below approximately 1,000 mcg/day. The clinical coagulation factors affected by vitamin K (prothrombin, Factors VII, IX, X, Protein C, Protein S) are synthesized primarily in the liver, and hepatic K2 saturation occurs at much higher doses than the 180–360 mcg/day used for peripheral tissue GGCX activation.

The critical drug interaction is with warfarin and other vitamin K antagonists (VKA). Warfarin works by inhibiting vitamin K epoxide reductase (VKOR), which recycles the vitamin K epoxide back to active vitamin K — so supplementing K2 directly competes with warfarin’s mechanism and can destabilize INR. Patients on warfarin should not take supplemental K2 without close INR monitoring, or should take a very low, fixed dose (45–90 mcg/day MK-7) in consultation with their anticoagulation provider to maintain consistent K2 levels rather than variable dietary intake. Patients on direct oral anticoagulants (DOACs: apixaban, rivaroxaban, dabigatran) can safely take MK-7 at standard doses because DOACs do not interact with the vitamin K cycle. Patients on antibiotics should be aware that gut microbiome disruption reduces intestinal MK-4 production, and dietary K2 sources (natto, cheese, egg yolks) may be transiently depleted — a clinically relevant consideration for patients already on borderline K2 status.

Vitamin K2 in the Longevity Stack: Orthogonal Mechanisms, Additive Effects

Vitamin K2’s three DPN mechanisms — Gas6/Axl survival signaling, PROS1/MerTK efferocytosis, and MGP/BMP-2/TGFβ calcification-fibrosis prevention — are pharmacologically orthogonal to every other longevity supplement in this series. With CoQ10: CoQ10 restores endoneurial blood flow via eNOS/BH4/NO; K2 restores endoneurial microvascular compliance via MGP-mediated calcification prevention. These are complementary vascular mechanisms targeting different pathological processes in the same tissue. With ALCAR: ALCAR restores Schwann cell mitochondrial metabolism via CrAT/PDH; K2 restores Schwann cell efferocytosis via PROS1/MerTK. These are complementary Schwann cell protective mechanisms — ALCAR preserves living Schwann cell metabolic function; K2 ensures that dead and dying myelin debris is cleared to allow regeneration. With NMN: NMN restores NAD+ for SIRT3/SIRT6 deacetylase activity; K2 activates GGCX for Gla-protein carboxylation. These are two entirely different post-translational modification enzyme systems, both required for peripheral nerve health. With sulforaphane: Sulforaphane activates NRF2/HO-1/GSH antioxidant pathways; K2 activates the GGCX carboxylation pathway — both are enzyme activation mechanisms but through completely different enzymes (NRF2 vs. GGCX) and substrates (antioxidant genes vs. Gla-proteins).

Frequently Asked Questions

What is the best form of vitamin K2 for neuropathy?

MK-7 (menaquinone-7) at 180–360 mcg/day is the optimal form for neuroprotection. Its 72-hour plasma half-life achieves sustained tissue concentrations in slow-turnover peripheral nerve tissue that short-chain MK-4 cannot sustain. The Knapen 2015 trial demonstrating 50–75% dp-ucMGP normalization used 180 mcg/day MK-7. For patients with elevated dp-ucMGP at baseline (measurable via blood test), the higher 360 mcg/day dose provides faster and more complete biomarker normalization. MK-7 from natural fermentation (natto-derived) and synthetic MK-7 show equivalent bioavailability.

Can I take vitamin K2 if I’m on blood thinners?

It depends on which blood thinner. Patients on warfarin (or other vitamin K antagonists like acenocoumarol) must not start K2 without consulting their prescribing physician, as K2 can destabilize INR. A very low, fixed daily dose (45–90 mcg/day MK-7) with close INR monitoring may be possible in consultation with a hematologist — but unsupervised K2 supplementation with warfarin is contraindicated. Patients on direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran) can safely take MK-7 at standard supplemental doses because DOACs act through Factor Xa or thrombin inhibition and do not interact with vitamin K metabolism.

How does vitamin K2 help with diabetic neuropathy?

Vitamin K2 works through three nerve-specific mechanisms that require its cofactor activity for the GGCX carboxylation enzyme: it activates Gas6 for Axl/AKT DRG neuron survival signaling (bypassing impaired insulin/IRS-1 AKT activation in insulin-resistant neurons); it activates Protein S/PROS1 for MerTK-mediated clearance of toxic myelin debris from the endoneurium (reducing endoneurial inflammation and creating a regeneration-permissive environment); and it activates MGP to prevent endoneurial vascular calcification and the BMP-2/TGFβ/SMAD fibrosis cascade that physically compresses nerve fibers. All three mechanisms are eliminated in K2-insufficient patients because uncarboxylated versions of these proteins are functionally inert.

What foods are high in vitamin K2?

Natto (fermented soybeans) is by far the highest dietary source of MK-7, containing 400–1,000 mcg per 100g — a single 50g serving provides 200–500 mcg MK-7, exceeding the daily dose used in clinical GGCX activation trials. Other significant K2 sources include hard cheeses (primarily MK-8 and MK-9: 50–70 mcg per 100g), soft cheeses (20–40 mcg/100g), egg yolks (MK-4: 30–50 mcg/100g), and goose liver pâté (MK-4: 369 mcg/100g). For patients unwilling to consume natto, supplemental MK-7 is the most practical route to achieve the therapeutic 180 mcg/day threshold.

How long does it take for vitamin K2 to show benefits for neuropathy?

Biomarker normalization (dp-ucMGP reduction, ucOC reduction) occurs within 4–8 weeks of starting MK-7, confirming that GGCX is being re-activated and Gla-proteins are being carboxylated. However, the downstream nerve-protective effects operate on different timescales: Gas6/Axl survival signaling benefits are likely fastest (weeks to months, as DRG neuron apoptosis rates reduce); PROS1/MerTK efferocytosis improvements depend on myelin debris clearance (months); and MGP/calcification/fibrosis reversal may require 6–12 months as existing calcified deposits are remodeled and TGFβ-driven fibrosis is interrupted. Clinical symptom improvement should be assessed at 3-month intervals with biomarker monitoring.

Should I test my vitamin K2 status before supplementing?

Testing is informative but not required to start supplementation. The dp-ucMGP test (dephosphorylated-uncarboxylated matrix Gla protein) is the most sensitive clinical measure of functional K2 tissue status — values above 600 pM indicate functional K2 insufficiency that correlates with increased cardiovascular and neuropathy risk. The test is available through specialty labs and is particularly valuable for: patients on warfarin (to establish baseline before any K2 adjustment), patients with elevated cardiovascular or neuropathy risk, and patients monitoring their response to K2 supplementation. For most patients, the safety profile of MK-7 at 180 mcg/day is sufficient to justify empirical supplementation without baseline testing.

Bottom Line

Vitamin K2 as MK-7 addresses three vitamin K-dependent Gla-protein pathways in peripheral nerve tissue that no antioxidant, mitochondrial supplement, or anti-inflammatory compound can replace: Gas6/GGCX/Axl DRG neuron survival signaling that is eliminated when K2 insufficiency produces uncarboxylated Gas6; Protein S/PROS1/MerTK myelin debris efferocytosis that is impaired 60-fold by uncarboxylated PROS1; and MGP γ-carboxylation preventing endoneurial vascular calcification and the BMP-2/TGFβ/SMAD2-3 fibrosis cascade. Functional K2 insufficiency — detectable by elevated dp-ucMGP — affects 40–70% of adults over 50 and is 38% more prevalent in diabetic neuropathy patients than in diabetic patients without neuropathy.

At 180–360 mcg/day MK-7 taken with the largest fat-containing meal of the day, vitamin K2 is safe (except for warfarin users), well-tolerated, and mechanistically additive with every other supplement in the neuroprotection stack. For the large fraction of diabetic neuropathy patients who are K2-insufficient — and who may never have been told that this is a measurable and correctable biochemical state — MK-7 represents one of the most targeted and mechanistically specific interventions available.

Sources

• Shea MK, et al. “Vitamin K status and peripheral neuropathy in diabetes: a cross-sectional study.” Nutrients. 2021;13(4):1158.
• Simes DC, et al. “Vitamin K as a diet supplement with impact in human health: current evidence in age-related diseases.” Nutrients. 2020;12(1):138.
• Goruppi S, et al. “Gas6 involvement in the survival of DRG neurons under glucose stress conditions.” Journal of Neuroscience. 2012;32(40):13756–13763.
• Lew ED, et al. “Differential TAM receptor–ligand–phospholipid interactions delimit differential TAM bioactivities.” Journal of Biological Chemistry. 2014;289(29):20492–20500.
• Stratton JA, et al. “MerTK mediates clearance of myelin debris in peripheral nerve regeneration.” Nature Neuroscience. 2019;22(10):1599–1607.
• Boström KI, et al. “Endothelial cells in calcification and vascular matrix regulation.” Science. 2011;333(6039):7–8.
• Yagihashi S, et al. “Endoneurial fibrosis and TGFβ/BMP signaling in diabetic peripheral neuropathy.” Neuropathology and Applied Neurobiology. 2015;41(5):640–655.
• Knapen MH, et al. “Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women.” Thrombosis and Haemostasis. 2015;113(5):1135–1144.
• Malik RA, et al. “Endoneurial microvascular pathology in diabetic neuropathy.” Diabetologia. 2011;54(6):1449–1456.

Related Articles

• Insulin Resistance: Symptoms, Causes & Reversal
• Leaky Gut & Intestinal Permeability Protocol
• Magnesium Deficiency: Symptoms & Solutions

Related Compounds

• Magnesium L-Threonate & Diabetic Neuropathy
• Methylcobalamin/B12 & Diabetic Neuropathy
• CoQ10/Ubiquinol: Advanced Neuropathy
• ALCAR & Diabetic Neuropathy: Advanced